Organovo Holdings ( (ONVO) ) has issued an update.
On March 27, 2025, Organovo Holdings announced the completion of the sale of its FXR Program to Lilly, resulting in upfront payments and anticipated future milestone payments. This transaction, along with funds from previous warrant exercises and equity sales, positions the company to pursue new IBD opportunities while reducing expenditures related to the FXR314 program. Organovo’s 3D human cellular models have shown promising results in IBD, and the company plans to leverage its capital to explore further therapeutic opportunities. In 2024, FXR314 demonstrated significant potential in treating IBD and liver fibrosis, with notable data presented at several key medical conferences.
More about Organovo Holdings
Organovo Holdings, Inc. is a clinical stage biotechnology company that focuses on developing novel treatment approaches for inflammatory bowel disease (IBD). The company utilizes proprietary technology to create three-dimensional (3D) human tissues that replicate key aspects of native human tissue composition, architecture, function, and disease.
YTD Price Performance: -50.36%
Average Trading Volume: 681,152
Technical Sentiment Signal: Buy
Current Market Cap: $4.66M
Find detailed analytics on ONVO stock on TipRanks’ Stock Analysis page.